MedTrace Logo

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer

NCT01916837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2013-08-06

No results posted yet for this study

Summary

In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment recommendations.

Conditions

Interventions

OTHER

Sampling of tumor tissue

Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery

OTHER

Sampling of tumor tissue after breast cancer surgery

Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery

PROCEDURE

Sampling of tumor tissue after breast cancer surgery

Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01916837 on ClinicalTrials.gov